Dermatologists' Educational Demonstration for Epiduo Application

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02192632

Enrollment

Registered

2014-07-17

Start date

2014-01-31

Completion date

2015-02-28

Last updated

2015-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial Acne, Local Adverse Effects

Brief summary

The purpose of this study is to evaluate the efficacy and tolerability of this combination gel compared with BPO monotherapy in Korean patients, and test clinical practicability of dermatologists' educational demonstration for how to apply this gel in reducing uncomfortable irritations.

Interventions

DRUGEpiduo once daily with detailed instruction for how to apply it

DRUGEpiduo- once daily, simple instruction for application

DRUGBPO once daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* mild to moderate acne were evaluated by Leeds revised acne grade from 2 to 6 * age: 18-40

Exclusion criteria

* pregnancy * mental illness * intake of oral isotretinoin within 6 months * application of the other oral or topical acne medications * chemical peeling or light based treatments within 6 weeks.

Design outcomes

Primary

Measure	Time frame	Description
Percentile reduction of non-inflammatory & inflammatory acne lesions	12 weeks	Measurement of decreases in both non-inflammatory & inflammatory acne lesions

Secondary

Measure	Time frame	Description
Total number of local irriation effect counts (erythema, scaling, dryness, itching)	12 week	Calcuation of total number of local irriation effect counts (erythema, scaling, dryness, itching)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026